 SEATTLE--BUSINESS WIRE--Omeros Corporation Nasdaq: OMER today announced that the U.S. Food and Drug Administration FDA notified the company that, as part of FDAs ongoing review of the companys Biologics License Application BLA for narsoplimab in the treatment of hematopoietic stem cell transplant-associated thrombotic microangiopathy HSCT-TMA, FDA has identified deficiencies that preclude discussion of labeling and post-marketing requirementscommitments at this time. FDA stated tha 